Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Net revenues:
Total net revenues	$ 2,309	$ 1,366	$ 4,078	$ 2,351
Cost of goods sold	942	536	1,713	1,054
Gross margin	1,367	830	2,365	1,297
Operating expenses:
Research and development	793	352	1,549	641
Depreciation and amortization	48	40	98	81
Selling, general and administrative	1,403	1,091	2,906	2,351
Change in fair value of contingent consideration	(9)		(19)
Total operating expenses	2,235	1,483	4,534	3,073
Loss from operations	(868)	(653)	(2,169)	(1,776)
Other income (expense):
Loss on extinguishment of debt				(199)
Interest expense	(46)	(28)	(92)	(114)
Interest income		1		2
Other expense, net	(28)	(2)	(30)	(24)
Net loss	(942)	(682)	(2,291)	(2,111)
Less: Undeclared deemed dividend attributable to noncontrolling interest	(61)		(120)
Net loss attributable to Nephros, Inc. shareholders	$ (1,003)	$ (682)	$ (2,411)	$ (2,111)
Net loss per common share, basic and diluted	$ (0.14)	$ (0.10)	$ (0.33)	$ (0.32)
Weighted average common shares outstanding, basic and diluted	7,387,930	7,028,410	7,259,491	6,647,856
Comprehensive loss:
Net loss	$ (942)	$ (682)	$ (2,291)	$ (2,111)
Other comprehensive (loss) income, foreign currency translation adjustments, net of tax	2	(6)	(1)	(3)
Comprehensive loss	(940)	(688)	(2,292)	(2,114)
Comprehensive loss attributable to noncontrolling interest	(61)		(120)
Comprehensive loss attributable to Nephros, Inc. shareholders	(1,001)	(688)	(2,412)	(2,114)
Product Revenues [Member]
Net revenues:
Total net revenues	2,284	1,216	4,013	2,174
Royalty and Other Revenues [Member]
Net revenues:
Total net revenues	$ 25	$ 150	$ 65	$ 177